HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development

PLoS Pathogens

Volumn 10, Issue 5, 2014, Pages

  Verkoczy, Laurent ^a   Kelsoe, Garnett ^a   Haynes, Barton F ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

DRUG DEVELOPMENT; GENETICS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MUTATION; PROCEDURES; STANDARDS;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; AUTOANTIBODIES; DRUG DISCOVERY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE TOLERANCE; MUTATION;

EID: 84901653387     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004073     Document Type: Article

References (46)

1. Plotkin S, (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065.
2. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
3. McElrath MJ, Haynes BF, (2010) Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554.
4. Mascola JR, Haynes BF, (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254: 225-44.
5. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15: 951-954.
6. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433.
7. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, et al. (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 109: 18921-18925.
8. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503: 224-228.
9. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84.
10. Bonsignori M, Alam SM, Liao HX, Verkoczy L, Tomaras GD, et al. (2012) HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol 20: 532-539.
11. Stamatatos L, Morris L, Burton DR, Mascola JR, (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nature Med 15: 866-870.
12. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
13. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM, (2005) Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 14: 59-67.
14. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, et al. (2003) Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377.
15. Verkoczy L, Kelsoe G, Moody MA, Haynes BF, (2011) Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 23: 383-390.
16. Meffre E, Milili M, Blanco-Betancourt C, Antunes H, Nussenzweig MC, et al. (2001) Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest 108: 879-886.
17. Von Boehmer H, Melchers F, (2010) Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 11: 176-183.
18. Verkoczy L, Diaz M, Holl TM, Ouyang Y-B, Bouton-Verville H, et al. (2010) Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 107: 181-186.
19. Verkoczy L, Chen Y, Bouton-Verville H, Zhang J, Diaz M, et al. (2011) Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH×VL knockin mice reveals multiple tolerance controls. J Immunol 187: 3785-3797.
20. Chen Y, Zhang J, Hwang K-K, Bouton-Verville H, Xia S-M, et al. (2013) Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J Immunol 191: 1260-1275.
21. Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, et al. (2013) Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10. J Immunol 191: 3186-3191.
22. Finton KA, Larimore K, Larman HB, Friend D, Correnti C, et al. (2013) Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog 9: e1003639.
23. Alam SM, Liao HX, Dennison SM, Jaeger F, Parks R, et al. (2011) Differential reactivity germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J Virol 85: 11725-11731.
24. Zhang J, Alam SM, Bouton-Verville H, Chen Y, Newman A, et al. (2014) Modulation of non-neutralizing gp41 responses by an MHC-restricted TH epitope overlapping those of MPER broad neutralizing antibodies. J Immunol 192: 1693-1706.
25. Liao HX, Chen X, Munshaw S, Zhang R, Marshall DJ, et al. (2011) Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 208: 2237-2249.
26. Haynes BF, Kelsoe G, Harrison SC, Kepler TB, (2012) B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotech 30: 423-433.
27. Nemazee D, Burki K, (1989) Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337: 562-566.
28. Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, et al. (1991) Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 349: 331-334.
29. Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, et al. (1991) Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353: 765-769.
30. Goodnow CC, (1992) Transgenic mice and analysis of B-cell tolerance. Ann Rev Immunol 10: 489-518.
31. Yang G, Holl TM, Liu Y, Li X, Nicely N, et al. (2013) Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 210: 241-256.
32. Verkoczy L, Chen Y, Zhang J, Bouton-Verville H, Neman A, et al. (2013) Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against MPER-associated autoreactivity limits T-dependent responses. J Immunol 191: 2538-2550.
33. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412.
34. Ota T, Doyle-Cooper C, Cooper AB, Doores KJ, Aoki-Ota M, et al. (2013) B cells from Knock-in Mice Expressing Broadly Neutralizing HIV Antibody b12 Carry an Innocuous B Cell Receptor Responsive to HIV Vaccine Candidates. J Immunol 191: 3179-85.
35. Liao H-X, Lynch R, Zhou Z, Gao G, Alam SM, et al. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-76.
36. Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, et al. (2012) Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. J Immunol 189: 4816-4824.
37. Chen J, Lansford R, Stewart V, Young F, Alt FW, (1993) RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. Proc Natl Acad Sci USA 90: 4528-4532.
38. Batista FD, Neuberger MS, (1998) Affinity Dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8: 751-759.
39. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, et al. (2013) Somatic mutations of the immunoglobulin framework are generally required for broad and potent neutralization. Cell 153: 126-138.
40. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, et al. (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18: 1688-1692.
41. Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, et al. (2013) Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bnAbs. PLoS Pathog 9: e1003106.
42. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, et al. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 106: 20234-20239.
43. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, et al. (2010) Polyreactivity increases the apparaent affinity of anti-HIV antibodies by hereoligation. Science 467: 591-595.
44. Jardine J, Julien J-P, Menis S, Ota T, Kalyuzhniy O, et al. (2013) Rational HIV immunogen design to target specific germline B cell receptors. Science 340: 711-716.
45. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, et al. (2013) Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 210: 655-663.
46. Dormitzer PR, Grandi G, Rappuoli R, (2012) Structural vaccinology starts to deliver. Nat Rev Microbiol 10: 807-813.